Severe thrombocytopenia possibly related to readministration of eptifibatide.
Thrombocytopenia following eptifibatide therapy is a rare event, and acute severe thrombocytopenia following readministration has not been reported. We describe a case of acute severe thrombocytopenia following reexposure to eptifibatide during percutaneous coronary intervention. We continue to monitor platelet counts at 2-4 hr and 16-24 hr following administration of any glycoprotein IIb/IIIa inhibitor. Cathet Cardiovasc Intervent 2001;54:63-67.